scholarly article by Kevin W Garey et al published 23 October 2019 in Open Forum Infectious Diseases

AttributesValues
rdf:type
description
  • wetenschappelijk artikel (nl)
  • article scientifique publié en 2019 (fr)
  • im Oktober 2019 veröffentlichter wissenschaftlicher Artikel (de)
  • наукова стаття, опублікована в жовтні 2019 (uk)
  • scholarly article by Kevin W Garey et al published 23 October 2019 in Open Forum Infectious Diseases (en)
publication date
publication date
author name string
author name string
  • Michael Silverman
  • Julie Mercier
  • Murray Ducharme
  • M Jahangir Alam
  • Kevin W Garey
  • Anne J Gonzales-Luna
  • Martin Kankam
  • Corinne Seng Yue
rdfs:label
  • LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
  • LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (nl)
skos:prefLabel
  • LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
  • LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (nl)
name
  • LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
  • LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (nl)
author
author
title
title
  • LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
page(s)
page(s)
  • S995-S996
instance of
instance of
main subject
main subject
published in
published in
issue
volume
issue
  • Suppl 2
volume
  • 6
DOI
DOI
DOI
  • 10.1093/OFID/OFZ415.2490
copyright license
copyright status
copyright license
copyright status
PMCID
PMCID
  • 6810073
is about of
is cites work of
is cites work of
Faceted Search & Find service v1.16.117 as of May 05 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software